Company attributes
Other attributes
Palatin Technologies, Inc. is a biopharmaceutical company. It is a company that engages in the development of medicines, based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its product candidates are targeted, receptor-specific therapeutics for treating diseases with unmet and challenging medical need and commercial potential. Palatin is equipped with a novel approach for resolving inflammation and it has expertise in drug discovery.
The company's melanocortin receptor (MCr) system is hormone driven and it has effects on food intake, metabolism, sexual function, inflammation and immune system responses. The melanocortin receptors are five, which ranges from MC1r to MC5r.
Its natriuretic peptide receptor system regulates cardiovascular functions, and the therapeutic agents that modulate this system have the potential of treating fibrotic diseases, cardiovascular diseases, and also reducing cardiac hypertrophy and fibrosis, acute asthma, heart failure, pulmonary diseases and hypertension.
